Extremely good post. Thanks.
Boehringer Ingelheim Pharmaceuticals would be a good partner. Avid already works with them. With their World Wide network of production facilities and high capacity, incl. cGMP compliance, it would certainly solve initial production problems.
BIP could also serve as a middle ground partner, not majorly driven by owning the pipeline but rather in producing the substance. That would give PPHM some flexibility and arm-power when another partner, that does sit there for Bavi specifically, joins the table.
However, at this point 2 extra seats would be more then sufficient, allowing PPHM to guard the poison pill and control possible acquisition offers, if that becomes a topic one day, until it reaches a critical mass and market cap and that a poison pill doesn't really serve its purpose any more.
Personally and currently I find that a majority in the BoD that has the intend to keep the poison pill in place and has a PERSONAL incentive to do so (eg: by their stock and options) and wouldn't hesitate to trigger it if hostile price offerings are insufficient, a plus for our investment.
Market Data 
Markets 
AI
